The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease

被引:284
作者
Brewster, UC [1 ]
Perazella, MA [1 ]
机构
[1] Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06520 USA
关键词
D O I
10.1016/j.amjmed.2003.09.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The renin-angiotensin-aldosterone system regulates renal vasomotor activity, maintains optimal salt and water homeostasis, and controls tissue growth in the kidney. However, pathologic consequences can result from overactivity of this cascade, involving it in the pathophysiology of kidney disease. An activated renin-angiotensin-aldosterone system promotes both systemic and glomerular capillary hypertension, which can induce hemodynamic injury to the vascular endothelium and glomerulus. In addition, direct profibrotic and proinflammatory actions of angiotensin II and aldosterone may also promote kidney damage. The majority of the untoward effects associated with angiotensin II appear to be mediated through its binding to the angiotensin II type I receptor. Aldosterone can also induce re-nal injury by binding to its receptor in the kidney. An understanding of this system is important to appreciate that inhibitors of this cascade can reduce the progression of chronic kidney disease in proteinuric disease states. Pharmacologic agents that can interfere with this cascade include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone receptor antagonists. This paper will provide an over-view of the renin-angiotensin system, review its role in kidney disease, examine the renal effects of inhibition of this cascade in experimental animal models, and review clinical studies utilizing renin-angiotensin-aldosterone inhibitors in patients with diabetic and nondiabetic nephropathies.(C)2004 by Excerpta Medica Inc.
引用
收藏
页码:263 / 272
页数:10
相关论文
共 70 条
  • [1] Nephrotoxicity of increased glomerular protein traffic
    Abbate, M
    Benigni, A
    Bertani, T
    Remuzzi, G
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (02) : 304 - 312
  • [2] Agarwal R, 2001, KIDNEY INT, V59, P2282, DOI 10.1046/j.1523-1755.2001.0590062282.x
  • [3] Role of angiotensin II and bradykinin in experimental diabetic nephropathy - Functional and structural studies
    Allen, TJ
    Cao, ZM
    Youssef, S
    Hulthen, UL
    Cooper, ME
    [J]. DIABETES, 1997, 46 (10) : 1612 - 1618
  • [4] CONTROL OF GLOMERULAR HYPERTENSION LIMITS GLOMERULAR INJURY IN RATS WITH REDUCED RENAL MASS
    ANDERSON, S
    MEYER, TW
    RENNKE, HG
    BRENNER, BM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (02) : 612 - 619
  • [5] Angiotensin II type 2 receptors in the kidney: evidence for endothelial-cell-mediated renal vasodilatation
    Arima, S
    Ito, S
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (04) : 448 - 451
  • [6] Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine - Is this a cause for concern?
    Bakris, GL
    Weir, MR
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (05) : 685 - 693
  • [7] Benigni A, 2001, J AM SOC NEPHROL, V12, P941, DOI 10.1681/ASN.V125941
  • [8] Bonnet F, 2001, DIABETOLOGIA, V44, P874
  • [9] BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104
  • [10] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869